§ Browsing ETD Metadata
System No. U0002-2606201120054900
Title (in Chinese) 人類卵巢癌細胞中 Chk2 蛋白的活化有助於黃芩素所誘導之 G2/M 細胞週期停滯
Title (in English) Activation of Chk2 contributes to baicalein-induced G2/M cell cycle arrest in human ovarian cancer cells
Other Title
Institution 淡江大學
Department (in Chinese) 化學學系碩士班
Department (in English) Department of Chemistry
Other Division
Other Division Name
Other Department/Institution
Academic Year 99
Semester 2
PublicationYear 100
Author's name (in Chinese) 邵韋勳
Author's name(in English) Wei-Syun Shao
Student ID 698160180
Degree 碩士
Language Traditional Chinese
Other Language
Date of Oral Defense 2011-06-16
Pagination 53page
Committee Member advisor - Tzu-Chao Chuang
co-chair - 陳銘凱
co-chair - 許世忠
Keyword (inChinese) 細胞檢查點激酶
Keyword (in English) Chk2
G2/M arrest
Other Keywords
Abstract (in Chinese)
類黃酮化合物是一種天然多酚類化合物,其持續攝取已經是被證實是可以促進身體健康、預防疾病產生以及防止癌症生成。在本研究中我們評估了類黃酮化合物-黃芩素 (Baicalein) 在人類卵巢癌的抗癌效果。經由實驗結果發現,在黃芩素的作用下,無論是隨著藥物作用濃度的提升或者是隨著作用時間的拉長,都會使得人類卵巢癌細胞之細胞生長能力受到明顯的抑制。然而,這些卵巢癌細胞在黃芩素作用下所導致的細胞生長抑制效果,是透過細胞週期 G2/M 停滯所造成。另外,經由實驗結果發現,黃芩素能夠誘導卵巢癌細胞內活性氧化物質 (ROS) 的生成量增加、H2AX 蛋白磷酸化和 Chk2蛋白的活化。除此之外,一些細胞週期 G2/M 的調控蛋白,如:Cdc25C、 Cdk1 以及 cyclin B1之蛋白質表現量也會在黃芩素的作用下而明顯下滑。綜合以上結果,人類卵巢癌細胞在黃芩素作用下所造成的細胞週期 G2/M 停滯現象,可能是由於 ROS 所導致的 DNA 受損而引發。
Abstract (in English)
Baicalein has been reported to exhibit anti-tumor activities. In this study, we examined the anti-proliferating effects of baicalein on ovarian cancer cells. We found that baicalein inhibited the cell growth of ovarian cancer cells. Besides, our results demonstrate that baicalein caused reactive oxygen species (ROS) generation, H2AX phosphorylation and Chk2 activation in ovarian cancer cells. Furthermore, we also observed that G2/M regulatory molecules such as Cdc25C, Cdk1, cyclin B1 were down-regulation by baicalein. Taken together, these data suggest baicalein may generate ROS to cause DNA damage and then results in G2/M arrest in ovarian cancer cells.
Other Abstract
Table of Content (with Page Number)
第一章 緒論...1
第一節 細胞檢查點激酶2...1
第二節 黃芩素...10
第二章 實驗目的...23
第三章 材料與方法...24
第四章 結果...28
第一節 實驗結果...28
第二節 實驗圖表...33
第五章 討論...39
第六章 結論...43
第七章 參考文獻...44
Abelson PH (1990) Medicine from plants. Science 247-513.

Ahn J, Urist M, Prives C (2004) The Chk2 protein kinase. DNA Repair 3, 1039-1047.

Antoni L, Sodha N, Collins I, Garrett MD (2007) CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer 7, 925-936.

Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217.

Barnhart BC, Alappat EC, Peter ME (2003) The CD95 type I/type II model. Semin Immunol 15, 185-193.

Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429.

Baumann S, Fas SC, Giaisi M, Müller WW, Merling A, Gülow K, Edler L, Krammer PH, Li-Weber M (2008) Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLC{gamma}1- and Ca2+-dependent apoptosis. Blood 111, 2354-2363. 

Blasina A, de Weyer IV, Laus MC, Luyten WH, Parker AE, McGowan CH (1999) A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr Biol 9, 1-10.

Brown JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23, 2840-2855.

Cao G, Sofic E, Prior RL (1997) Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic Biol Med 22, 749-760.

Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D (2007) Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 6, 935-944.

Castellone MD, Teramoto H, Gutkind JS (2006) Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. Cancer Res 66, 11085-11088. 

Chen YC, Shen SC, Chen LG, Lee TJ, Yang LL (2001) Wogonin, Baicalin and Baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochem Pharmacol 61, 1417-1427.

Chi YS, Lim H, Park H, Kim HP (2003) Effects of Wogonin, a plant flavone from Scutellaria radix, on skin inflammation: in vivo regulation of inflammationassociated gene expression. Biochem Pharmacol 66, 1271-1278.

Chung H, Jung YM, Shin DH, Lee JY, Oh MY, Kim HJ, Jang KS, Jeon SJ, Son KH, Kong G (2008) Anticancer effects of Wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts. Int J Cancer 122, 816-822.

Curtin JF, Donovan M, Cotter TG (2002) Regulation and measurement of oxidative stress in apoptosis. J Immunol Metohods 265, 49-72. 

Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymańska A, Szymańska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubiński J (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75, 1131-1135.

Debatin KM, Krammer PH (2004) Death receptors in chemotherapy and cancer. Oncogene 23, 2950-2966.

Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J (2001) The DNA synthesi ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistants. Nature 410, 842-847.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.

Galluzzi L, Larochette N, Zamzami N, Kroemer G (2006) Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25, 4812-4830. 

Gao Z, Huang K, Yang X, Xu H (1999) Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta 1472, 643-650.
Gao J, Sanchez-Medina A, Pendry BA, Hughes MJ, Webb GP, Corcoran O (2008) Validation of a HPLC method for flavonoid biomarkers in skullcap (Scutellaria) and its use to illustrate wide variability in the quality of commercial tinctures. J Pharm Pharm Sci 11, 77-87.

Han J, Ye M, Xu M, Sun J, Wang B, Guo D (2007) Characterization of flavonoids in the traditional Chinese herbal medicine-Huangqin by liquid chromatography coupled with electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 848, 355–362.

Haranaka R, Hasegawa R, Nakagawa S, Sakurai A, Satomi N, Haranaka K (1998) Antitumor activity of combination therapy with traditional Chinese medicine and OK432 or MMC. J Biol Response Mod 7, 77-90.

Havsteen BH (2002) The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96, 67-202.

Himeji M, Ohtsuki T, Fukazawa H, Tanaka M, Yazaki S, Ui S, Nishio K, Yamamoto H, Tasaka K, Mimura A (2007) Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid Wogonin among human cancer cells and normal diploid cell. Cancer Lett 245, 269-274.

Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, De Stanchina E, Bristow RG, Suda T, Lowe SW, Jeggo PA, Elledge SJ and Mak TW (2002) Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 22, 6521-6532.

Hong T, Jin GB, Cho S, Cyong JC (2002) Evaluation of the anti-inflammatory effect of Baicalein on dextran sulfate sodium-induced colitis in mice. Planta Med 68, 268-271.

Huang RL, Chen CC, Huang HL, Chang CG, Chen CF, Chang C, Hsieh MT (2000) Antihepatitis B virus effects of Wogonin isolated from Scutellaria baicalensis. Planta Med 66, 694-698.

Huang Y, Tsang SY, Yao X, Chen ZY (2005) Biological properties of Baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 5, 177-184.

Hull MA, Ko SC, Hawcroft G (2004) Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 3, 1031-1039.

Hussain SP, Hofseth LJ, Harris CC (2003) Radical causes of cancer. Nat Rev Cancer 3, 276-285.

Ikemoto S, Sugimura K, Yoshida N, Yasumoto R, Wada S, Yamamoto K, Kishimoto T (2000) Antitumor effects of Scutellariae radix and its components Baicalein, Baicalin and Wogonin on bladder cancer cell lines. Urology 55, 951-955.

Ingvarsson S, Sigbjornsdottir BI, Huiping C, Hafsteinsdottir SH, Ragnarsson G, Barkardottir RB, Arason A, Egilsson V, Bergthorsson JT (2002) Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 4, R4.

Jallepalli PV, Lengauer C, Vogelstein B, Bunz F (2003) The Chk2 tumor suppressor is not required for p53 responses in human cancer cells. J Biol Chem 278, 20475-20479.

James W Janetka and Susan Ashwell (2009) Checkpoint kinase inhibitors: a review of the patent literature. Expert Opin Ther Patents 19, 165-197.

Jin J, Ang XL, Ye X, Livingstone M, Harper JW (2008) Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase. J Biol Chem 283, 19322-19328.

Jobson AG, Cardellina JH 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R, Pommier Y (2007) Identification of a Bisguanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol 72, 876-884.

Kaestner P, Bastians H (2010) Mitotic drug targets. J Cell Biochem 111, 258-265.

Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432, 316-23.

Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3, 513-519.

Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H (2006) CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 43, e34.

Kim HK, Cheon BS, Kim YH, Kim SY, Kim HP (1999) Effects of naturally occurring flavonoids on nitric oxide production in the macrophage cell line RAW 264. 7 and their structure-activity relationships. Biochem Pharmacol 58, 759-765.

Kim H, Kim YS, Kim SY, Suk K (2001) The plant flavonoid Wogonin suppresses death of activated C6 rat glial cells by inhibiting nitric oxide production. Neurosci Lett 309, 67-71.

Kimura Y, Okuda H, Ogita Z (1997) Effects of flavonoids isolated from scutellaria radix on fibrinolytic system induced by trypsin in human umbilical vein endothelial cells. J Nat Prod 60, 598-601.

Kuo HM, Tsai HC, Lin YL, Yang JS, Huang AC, Yang MD, Hsu SC, Chung MC, Gibson Wood W, Chung JG (2009) Mitochondrial-dependent caspase activation pathway is involved in baicalein-induced apoptosis in human hepatoma J5 cells. Int J Oncol 35, 717-724

Kurz EU and Lees-Miller SP (2004) DNA damage-induced activation of ATM and ATMdependent signaling pathways. DNA Repair 3, 889-900.

Lee DH, Kim C, Zhang L, Lee YJ (2008) Role of p53, PUMA, and Bax in Wogonininduced apoptosis in human cancer cells. Biochem Pharmacol 75, 2020-2033.

Lee HZ, Leung HW, Lai MY, Wu CH (2005) Baicalein-induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells. Anticancer Res 25, 959-964.

Leung HW, Yang WH, Lai MY, Lin CJ, Lee HZ (2007) Inhibition of 12-lipoxygenase during baicalein-induced human lung nonsmall carcinoma H460 cell apoptosis. Food Chem Toxicol 45, 403-411.

Li-Weber M (2009) New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev 35, 57-68.

Lin CC, Shieh DE (1996) The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, Baicalin, Baicalein and Wogonin. Am J Chin Med 24, 31-36.

Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, Robertson S, Murray L, Karnitz LM (2007) Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6, 104-110.

Ma Z, Otsuyama K, Liu S, Abroun S, Ishikawa H, Tsuyama N, Obata M, Li FJ, Zheng X, Maki Y, Miyamoto K, Kawano MM (2005) Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 105, 3312-3318.

McPherson JP, Lemmers B, Hirao A, Hakem A, Abraham J, Migon E, Matysiak-Zablocki E, Tamblyn L, Sanchez-Sweatman O, Khokha R, Squire J, Hande MP, Mak TW and Hakem R (2004) Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev 18, 1144-1153.

Middleton Jr E, Kandaswami C, Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52, 673-751.

Miura YH, Tomita I, Watanabe T, Hirayama T, Fukui S (1998) Active oxygens generation by flavonoids. Biol Pharm Bull 21, 93 – 96.

Morel I, Lescoat G, Cillard P, Cillard J (1994) Role of flavonoids and iron chelation in antioxidant action. Methods Enzymol 234, 437-443.

Motoo Y, Sawabu N (1994) Antitumor effects of saikosaponins, Baicalin and Baicalein on human hepatoma cell lines. Cancer Lett 86, 91-95.

Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981–2002. J Nat Prod 66, 1022-1037.

Norbury CJ and Zhivotovsky B (2004) DNA damage-induced apoptosis. Oncogene 23, 2797-2808.

Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P (2003) The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 63, 8153-8157.

Park BK, Heo MY, Park H, Kim HP (2001) Inhibition of TPA-induced  yclooxygenase-2 expression and skin inflammation in mice by Wogonin, a plant flavone from Scutellaria radix. Eur J Pharmacol 425, 153-157.

Perona R, Moncho-Amor V, Machado-Pinilla R, Belda-Iniesta C, Sanchez Perez I (2008) Role of CHK2 in cancer development. Clin Transl Oncol 10, 538-542.

Pidgeon GP, Kandouz M, Meram A, Honn KV (2002) Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 62, 2721-2727.

Pires IM, Ward TH, Dive C (2010) Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors. Br J Pharmacol 159, 1326-1338.

Rhoads CP (1947) Report on a cooperative study of nitrogen mustard (HN2) therapy of neoplastic disesase. Trans Assoc Am Physicians 60, 110-111.

Rice-Evans CA, Miller NJ, Paganga G (1996) Structure-antioxidant activity relationships of flavonoids and phenlic acids. Free Radic Biol Med 20, 933-956.

Roy MK, Nakahara K, Na TV, Trakoontivakorn G, Takenaka M, Isobe S, Tsushida T (2007) Baicalein, a flavonoid extracted from a methanolic extract of Oroxylum indicum inhibits proliferation of a cancer cell line in vitro via induction of apoptosis. Harmazie 62, 149-153.

Sahu RP, Batra S and Srivastava SK (2009) Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer 100, 1425-1433.

Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23, 9408-9421.

Seppälä EH, Ikonen T, Autio V, Rökman A, Mononen N, Matikainen MP, Tammela TL, Schleutker J (2003) Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res 9, 5252-5256.

Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24, 1770-1783.

Shen SC, Lee WR, Lin HY, Huang HC, Ko CH, Yang LL, Chen YC (2002) In vitro and in vivo inhibitory activities of rutin, Wogonin, and quercetin on lipopolysaccharideinduced nitric oxide and prostaglandin E(2) production. Eur J Pharmacol 446, 187-194.

Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60, 3689-3695.

Stolz A, Ertych N, Kienitz A, Vogel C, Schneider V, Fritz B, Jacob R, Dittmar G, Weichert W, Petersen I, Bastians H (2010) The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol 12, 492-499.

Storz P (2005) Reactive oxygen species in tumor progression. Front Biosci 10, 1881-1896.

Subbaramaiah K, Dannenberg AJ (2003) Cyclooxygenase 2: a molecular target for cancer revention and treatment. Trends Pharmacol Sci 24, 96-102.

Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B, Magnowski P, Dziuba I, Gugala K, Debniak B, Gozdz S, Sokolenko AP, Krylova NY, Lobeiko OS, Narod SA, Lubinski J (2006) CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 102, 429-431.

Takai H, Naka K, Okada Y, Watanabe M, Harada N, Saito S, Anderson CW, Appella E, Nakanishi M, Suzuki H, Nagashima K, Sawa H, Ikeda K, Motoyama N (2002) Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. Embo J 21, 5195-5205.

Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6, 1024-1028.

Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160, 1-40.

Varley J, Haber DA (2003) Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res 5, 123-125.

Wakabayashi I, Yasui K (2000) Wogonin inhibits inducible prostaglandin E(2) production in macrophages. Eur J Pharmacol 406, 477-481.

Wang HK, Xia Y, Yang ZY, Natschke SL, Lee KH (1998) Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Adv Exp Med Biol 439, 191-225.

Wang Y, Wiltshire T, Senft J, Reed E and Wang W (2007) Irofulven induces replicationdependent CHK2 activation related to p53 status. Biochem Pharmacol 73, 469-480.
Williams LH, Choong D, Johnson SA, Campbell IG (2006) Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers. Clin Cancer Res 12, 6967-6972.

Woo AY, Cheng CH, Waye MM (2005) Baicalein protects rat cardiomyocytes from hypoxia/reoxygenation damage via a prooxidant mechanism. Cardiovasc Res 65, 244-253.

Wu X, Webster SR and Chen J (2001) Characterization of tumor-associated Chk2 mutations. J Biol Chem 276, 2971-2974.

Yano H, Mizoguchi A, Fukuda K, Haramaki M, Ogasawara S, Momosaki S, Kojiro M (1994) The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res 54, 448-454.

You KM, Jong HG, Kim HP (1999) Inhibition of cyclooxygenase/lipoxygenase from human platelets by polyhydroxylated/methoxylated flavonoids isolated from medicinal plants. Arch Pharm Res 22, 18-24.

Yu J, Liu H, Lei J, Tan W, Hu X, Zou G (2007) Antitumor activity of chloroform fraction of Scutellaria barbata and its active constituents. Phytother Res 21, 817-822.

Zhang DY, Wu J, Ye F, Xue L, Jiang S, Yi J, Zhang W, Wei H, Sung M, Wang W, Li X (2003) Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res 63, 4037-4043.

Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, Chung JH, Powell SN, Xia F (2004) CHK2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 24, 708-718.

Zhang R, Loganathan S, Humphreys I and Srivastava SK (2006) Benzyl isothiocyanate-induced DNA damage causes G2/M cell cycle arrest and apoptosis in human pancreatic cancer cells. J Nutr 136, 2728-2734.

Zhou BB and Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439.
Terms of Use
Within Campus
I request to embargo my thesis/dissertation for 5 year(s) right after the date I submit my Authorization Approval Form.
Agree to authorize disclosure on campus
Duration for delaying release from 5 years.
Outside the Campus
I grant the authorization for the public to view/print my electronic full text with royalty fee and contact me for receiving the payment.
Duration for delaying release from 5 years.

If you have any questions, please contact us!

Library: please call (02)2621-5656 ext. 2487 or email